FY2025 EPS Estimates for Liquidia Increased by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of Liquidia in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.64) per share for the year, up from their prior estimate of ($0.94). The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS and FY2029 earnings at $7.57 EPS.

Several other brokerages also recently weighed in on LQDA. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Liquidia in a research note on Wednesday, February 25th. Jefferies Financial Group upped their price objective on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, January 13th. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Stock Up 0.4%

Shares of LQDA opened at $34.52 on Thursday. The company’s 50-day simple moving average is $37.07 and its 200-day simple moving average is $30.84. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. Liquidia has a 1 year low of $11.26 and a 1 year high of $46.67. The stock has a market capitalization of $3.00 billion, a PE ratio of -23.97, a P/E/G ratio of 0.60 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $92.02 million during the quarter. The company’s quarterly revenue was up 3072.4% on a year-over-year basis.

Insider Buying and Selling at Liquidia

In related news, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at $21,686,717.42. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 21,142 shares of Liquidia stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $791,345.06. Following the sale, the insider owned 176,883 shares in the company, valued at $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 212,534 shares of company stock worth $7,964,719. Corporate insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On Liquidia

Large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC increased its stake in Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock valued at $298,547,000 after purchasing an additional 90,400 shares during the last quarter. Vanguard Group Inc. boosted its stake in Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after buying an additional 52,671 shares during the last quarter. Opaleye Management Inc. grew its holdings in Liquidia by 9.5% in the 2nd quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after buying an additional 215,000 shares during the period. Caprock Group LLC grew its holdings in Liquidia by 9.3% in the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock valued at $61,527,000 after buying an additional 151,832 shares during the period. Finally, TCG Crossover Management LLC acquired a new position in shares of Liquidia during the 3rd quarter valued at about $38,887,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Strong commercial traction for YUTREPIA — Liquidia reported YUTREPIA net product sales of $148.3M for full‑year 2025 and $90.1M in Q4, with >3,600 unique prescriptions and ~2,900 patients started since launch; management highlighted high prescription‑to‑start conversion and expanding prescriber adoption. This supports revenue growth expectations and de‑risking of the commercial story. GlobeNewswire Release
• Positive Sentiment: Improving profitability and balance sheet — the company reported its second consecutive profitable quarter (Q4 net income $14.6M; adjusted EBITDA $27.3M) and ended 2025 with ~$190.7M cash, giving Liquidia capacity to fund commercialization and development from operations. Quiver Quant / Release
• Positive Sentiment: Earnings context — Q4 EPS was $0.15. That beat the Zacks estimate ($0.08) and came with $92.0M total revenue for the quarter (huge YoY growth), which may calm concerns despite mixed consensus comparisons. Zacks
• Positive Sentiment: Bullish analyst revisions — HC Wainwright materially raised near‑ and long‑term EPS forecasts (including FY2026–FY2029 upside), signaling that some brokers are now modeling strong multi‑year earnings leverage from YUTREPIA and pipeline programs. That can support higher price targets. MarketBeat / HC Wainwright note
• Neutral Sentiment: Valuation debate — coverage pieces are asking whether it’s “too late” to buy after the recent share surge; these articles reflect elevated expectations and may increase short‑term volatility as investors debate whether price already prices in rapid growth. Yahoo: Is It Too Late?
• Negative Sentiment: High SG&A and full‑year loss — selling, general & administrative costs jumped 93% (to $157.2M) as the company built commercial infrastructure; Liquidia still reported a 2025 net loss of $68.9M (improved vs. 2024), so margin expansion depends on continuing strong product uptake. GlobeNewswire Release
• Negative Sentiment: Insider and institutional selling — multiple insiders have sold shares and a manager recently sold ~$5.1M worth of LQDA, while some large institutions trimmed positions; heavy insider/institutional selling can weigh on sentiment despite operational progress. The Motley Fool
• Negative Sentiment: Ongoing litigation risk — the company notes litigation with United Therapeutics that could threaten product availability in some indications; this remains a material binary risk for revenue sustainability. GlobeNewswire Release

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).